{
  "version": "1.1.0",
  "description": "Drug-drug interaction watchlist relevant to prescribing cascades in PLHIV",
  "last_updated": "2025-01-01",
  "severity_levels": {
    "CONTRAINDICATED": "Do not use together; risk of severe/fatal adverse event",
    "MAJOR": "Potentially life-threatening or requiring major management change",
    "MODERATE": "May worsen patient condition; may require dose adjustment or monitoring",
    "MINOR": "Minimally clinically significant; be aware"
  },
  "interactions": [
    {
      "id": "DDI001",
      "drug_a": "Ritonavir / Cobicistat (PI boosters)",
      "drug_a_class": "CYP3A4 inhibitor",
      "drug_b": "Simvastatin / Lovastatin",
      "drug_b_class": "Statin (CYP3A4 substrate)",
      "severity": "CONTRAINDICATED",
      "mechanism_es": "Inhibición de CYP3A4 por RTV/COBI → aumento masivo de niveles de estatina → riesgo de rabdomiólisis",
      "mechanism_en": "CYP3A4 inhibition by RTV/COBI → massive increase in statin levels → rhabdomyolysis risk",
      "consequence_es": "Rabdomiólisis, fallo renal agudo, potencialmente fatal",
      "consequence_en": "Rhabdomyolysis, acute kidney failure, potentially fatal",
      "management_es": "Contraindicado. Usar rosuvastatina (dosis máx 10mg), pravastatina o pitavastatina en su lugar.",
      "management_en": "Contraindicated. Use rosuvastatin (max 10mg), pravastatin, or pitavastatin instead.",
      "cascade_relevance_es": "Cascada: IP/r → dislipidemia → estatina. El riesgo crítico es si se prescribe simvastatina/lovastatina.",
      "cascade_relevance_en": "Cascade: PI/r → dyslipidemia → statin. Critical risk if simvastatin/lovastatin is prescribed."
    },
    {
      "id": "DDI002",
      "drug_a": "Ritonavir / Cobicistat",
      "drug_a_class": "CYP3A4 inhibitor",
      "drug_b": "Sildenafil / Tadalafil / Vardenafil (PDE5 inhibitors)",
      "drug_b_class": "PDE5 inhibitor",
      "severity": "MAJOR",
      "mechanism_es": "Inhibición de CYP3A4 → aumento de niveles de iPDE5 → hipotensión severa, priapismo",
      "mechanism_en": "CYP3A4 inhibition → increased PDE5i levels → severe hypotension, priapism",
      "consequence_es": "Hipotensión severa, síncope, priapismo",
      "consequence_en": "Severe hypotension, syncope, priapism",
      "management_es": "Si necesario, dosis muy reducidas con supervisión: sildenafilo máx 25mg/48h, tadalafilo máx 10mg/72h.",
      "management_en": "If necessary, very reduced doses with supervision: sildenafil max 25mg/48h, tadalafil max 10mg/72h.",
      "cascade_relevance_es": "Cascada: ISRS/antipsicótico → disfunción sexual → iPDE5. Riesgo aumentado si hay IP/r.",
      "cascade_relevance_en": "Cascade: SSRI/antipsychotic → sexual dysfunction → PDE5i. Increased risk with PI/r."
    },
    {
      "id": "DDI003",
      "drug_a": "Dolutegravir / Bictegravir",
      "drug_a_class": "INSTI",
      "drug_b": "Metformin",
      "drug_b_class": "Biguanide antidiabetic",
      "severity": "MODERATE",
      "mechanism_es": "Inhibición del transportador OCT2/MATE por DTG/BIC → reducción de eliminación renal de metformina → aumento de niveles de metformina",
      "mechanism_en": "OCT2/MATE transporter inhibition by DTG/BIC → reduced renal metformin elimination → increased metformin levels",
      "consequence_es": "Acidosis láctica por metformina (raro pero grave), hipoglucemia",
      "consequence_en": "Metformin-induced lactic acidosis (rare but serious), hypoglycemia",
      "management_es": "Monitorizar función renal. Considerar reducción de dosis de metformina. Evitar metformina si TFGe <45.",
      "management_en": "Monitor renal function. Consider reducing metformin dose. Avoid metformin if eGFR <45.",
      "cascade_relevance_es": "Cascada: INSTI → ganancia de peso/DM2 → metformina. La combinación requiere vigilancia.",
      "cascade_relevance_en": "Cascade: INSTI → weight gain/T2DM → metformin. Combination requires vigilance."
    },
    {
      "id": "DDI004",
      "drug_a": "Efavirenz / Nevirapine / Rifampicin",
      "drug_a_class": "CYP3A4/CYP2B6 inducer",
      "drug_b": "Warfarin / Direct oral anticoagulants",
      "drug_b_class": "Anticoagulant",
      "severity": "MAJOR",
      "mechanism_es": "Inducción de CYP3A4/CYP2C9 → reducción de niveles de anticoagulantes → riesgo trombótico o necesidad de ajuste de dosis",
      "mechanism_en": "CYP3A4/CYP2C9 induction → reduced anticoagulant levels → thrombotic risk or need for dose adjustment",
      "consequence_es": "Pérdida de eficacia anticoagulante, riesgo de trombosis. Con warfarina: INR impredecible.",
      "consequence_en": "Loss of anticoagulant efficacy, thrombosis risk. With warfarin: unpredictable INR.",
      "management_es": "Monitorizar INR frecuentemente con warfarina. Con ACODs, considerar alternativas ARV. No hay datos suficientes para muchos ACODs con EFV.",
      "management_en": "Monitor INR frequently with warfarin. With DOACs, consider alternative ARVs. Insufficient data for many DOACs with EFV.",
      "cascade_relevance_es": "Pueden prescribirse anticoagulantes como parte de una cascada (p.ej., FA inducida por HTA no controlada).",
      "cascade_relevance_en": "Anticoagulants may be prescribed as part of a cascade (e.g., AF induced by uncontrolled hypertension)."
    },
    {
      "id": "DDI005",
      "drug_a": "Ritonavir / Cobicistat",
      "drug_a_class": "CYP3A4/P-gp inhibitor",
      "drug_b": "Midazolam / Triazolam (oral)",
      "drug_b_class": "Benzodiazepine (CYP3A4 substrate)",
      "severity": "CONTRAINDICATED",
      "mechanism_es": "Inhibición masiva de CYP3A4 → aumento extremo de benzodiacepinas → sedación profunda/coma respiratorio",
      "mechanism_en": "Massive CYP3A4 inhibition → extreme benzodiazepine accumulation → deep sedation/respiratory coma",
      "consequence_es": "Sedación profunda, depresión respiratoria, coma",
      "consequence_en": "Deep sedation, respiratory depression, coma",
      "management_es": "Contraindicado con midazolam/triazolam orales. El midazolam IV puede usarse con monitorización estricta.",
      "management_en": "Contraindicated with oral midazolam/triazolam. IV midazolam may be used with strict monitoring.",
      "cascade_relevance_es": "Cascada: EFV/ARV → insomnio → benzodiacepina. Riesgo crítico si hay IP/r concomitante.",
      "cascade_relevance_en": "Cascade: EFV/ARV → insomnia → benzodiazepine. Critical risk if PI/r concomitant."
    },
    {
      "id": "DDI006",
      "drug_a": "Ritonavir",
      "drug_a_class": "CYP3A4 inhibitor",
      "drug_b": "Colchicine",
      "drug_b_class": "Antigout agent",
      "severity": "MAJOR",
      "mechanism_es": "Inhibición de CYP3A4 y P-gp → aumento de niveles de colchicina → toxicidad grave",
      "mechanism_en": "CYP3A4 and P-gp inhibition → increased colchicine levels → severe toxicity",
      "consequence_es": "Toxicidad por colchicina: miopatía, neuropatía, supresión medular, fallo multiorgánico",
      "consequence_en": "Colchicine toxicity: myopathy, neuropathy, bone marrow suppression, multi-organ failure",
      "management_es": "Reducir significativamente la dosis de colchicina. Considerar alternativas para la gota (AINEs con precaución, corticoides).",
      "management_en": "Significantly reduce colchicine dose. Consider alternatives for gout (NSAIDs with caution, corticosteroids).",
      "cascade_relevance_es": "Cascada: Tiazida → gota → colchicina. En PVVIH con IP/r, riesgo de toxicidad grave por colchicina.",
      "cascade_relevance_en": "Cascade: Thiazide → gout → colchicine. In PLHIV on PI/r, risk of severe colchicine toxicity."
    },
    {
      "id": "DDI007",
      "drug_a": "Efavirenz",
      "drug_a_class": "CYP3A4 inducer",
      "drug_b": "Methadone",
      "drug_b_class": "Opioid (CYP3A4/CYP2B6 substrate)",
      "severity": "MAJOR",
      "mechanism_es": "Inducción de CYP2B6/CYP3A4 por EFV → reducción significativa de niveles de metadona → síndrome de abstinencia",
      "mechanism_en": "EFV induction of CYP2B6/CYP3A4 → significant reduction in methadone levels → withdrawal syndrome",
      "consequence_es": "Síndrome de abstinencia a opioides, recaída en adicción",
      "consequence_en": "Opioid withdrawal syndrome, relapse in addiction",
      "management_es": "Monitorizar síntomas de abstinencia; puede requerirse aumento de dosis de metadona de 30-50%.",
      "management_en": "Monitor for withdrawal symptoms; methadone dose increase of 30-50% may be required.",
      "cascade_relevance_es": "Puede desencadenar cascada: EFV → reducción de niveles de metadona → síntomas de abstinencia → nuevos opioides prescritos.",
      "cascade_relevance_en": "Can trigger cascade: EFV → reduced methadone levels → withdrawal symptoms → new opioids prescribed."
    },
    {
      "id": "DDI008",
      "drug_a": "Tenofovir DF",
      "drug_a_class": "NRTI",
      "drug_b": "NSAIDs / Aminoglycosides / Contrast agents",
      "drug_b_class": "Nephrotoxic agents",
      "severity": "MODERATE",
      "mechanism_es": "Nefrotoxicidad aditiva/sinérgica → mayor riesgo de disfunción renal aguda",
      "mechanism_en": "Additive/synergistic nephrotoxicity → greater risk of acute renal dysfunction",
      "consequence_es": "Fallo renal agudo, síndrome de Fanconi",
      "consequence_en": "Acute kidney failure, Fanconi syndrome",
      "management_es": "Evitar AINEs regulares en pacientes con TDF. Si necesarios, usar brevemente y monitorizar función renal.",
      "management_en": "Avoid regular NSAIDs in patients on TDF. If needed, use briefly and monitor renal function.",
      "cascade_relevance_es": "Cascada: TDF + AINE → nefrotoxicidad → medicamentos adicionales. Importante identificar.",
      "cascade_relevance_en": "Cascade: TDF + NSAID → nephrotoxicity → additional medications. Important to identify."
    },
    {
      "id": "DDI009",
      "drug_a": "Any QT-prolonging ARV (saquinavir, rilpivirine high-dose, lopinavir/r)",
      "drug_a_class": "QT-prolonging ARV",
      "drug_b": "Macrolides / Fluoroquinolones / Antifungals / Antipsychotics / Antidepressants (TCA)",
      "drug_b_class": "QT-prolonging agents",
      "severity": "MAJOR",
      "mechanism_es": "Prolongación aditiva del intervalo QT → riesgo de torsades de pointes",
      "mechanism_en": "Additive QT prolongation → torsades de pointes risk",
      "consequence_es": "Torsades de pointes, fibrilación ventricular, muerte súbita",
      "consequence_en": "Torsades de pointes, ventricular fibrillation, sudden death",
      "management_es": "Monitorizar ECG. Evitar combinaciones de múltiples agentes que prolongan QT. Verificar electrolitos.",
      "management_en": "Monitor ECG. Avoid combinations of multiple QT-prolonging agents. Check electrolytes.",
      "cascade_relevance_es": "Cascada: Antipsicótico (cascada del ISRS) + ARV que prolonga QT = riesgo aditivo.",
      "cascade_relevance_en": "Cascade: Antipsychotic (from SSRI cascade) + QT-prolonging ARV = additive risk."
    },
    {
      "id": "DDI010",
      "drug_a": "Cobicistat",
      "drug_a_class": "Pharmacokinetic enhancer (CYP3A4 inhibitor)",
      "drug_b": "Inhaled/intranasal corticosteroids (fluticasone, budesonide)",
      "drug_b_class": "Corticosteroid (CYP3A4 substrate)",
      "severity": "MAJOR",
      "mechanism_es": "Inhibición de CYP3A4 por cobicistat → acumulación de corticoide inhalado → síndrome de Cushing iatrogénico",
      "mechanism_en": "Cobicistat CYP3A4 inhibition → inhaled corticosteroid accumulation → iatrogenic Cushing syndrome",
      "consequence_es": "Síndrome de Cushing, supresión suprarrenal, osteoporosis, hiperglucemia, cataratas",
      "consequence_en": "Cushing syndrome, adrenal suppression, osteoporosis, hyperglycemia, cataracts",
      "management_es": "Preferir beclometasona inhalada (menos susceptible a CYP3A4) o valorar cambio de ARV sin cobicistat.",
      "management_en": "Prefer inhaled beclomethasone (less susceptible to CYP3A4) or consider switching to ARV without cobicistat.",
      "cascade_relevance_es": "Cascada doble: Cobicistat + corticoide inhalado → Cushing → hiperglucemia → antidiabético; osteoporosis → bisfosfonato.",
      "cascade_relevance_en": "Double cascade: Cobicistat + inhaled corticosteroid → Cushing → hyperglycemia → antidiabetic; osteoporosis → bisphosphonate."
    }
  ]
}
